Evidence-Based Smoking Cessation

Stephen Brunton, MD, Director of Faculty Development, Cabarrus Family Medicine, Charlotte, North Carolina, reviews the evidence on recent advances in smoking cessation and the novel agent varenicline, an alpha 4 beta 2 Nicotinic Acetylcholine Receptor Partial Agonist.

References and Resources
Gonzales D, Rennard SI, Nides M, et al, for the Varenicline Phase 3 Study Group. Varenicline, an ?4?2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA. 2006;296:47-55.
Click Here to read the article.

Covey LS, Glassman AH, Jiang H, A randomized trial of bupropion and/or nicotine gum as maintenance treatment for preventing smoking relapse. Addiction. 2007 Aug;102(8):1292-302.
Click Here to read abstract.

Dr. Brunton has disclosed the following:
Consulting Fees: Pfizer, Novo Nordisk, Amylin, Takeda, Novartis

Sponsored by The Doctor’s Channel